Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMA-CNS: age-adjusted high-dose chemotherapy with autologous stem cell transplantation versus conventional R-MP chemotherapy in elderly primary CNS lymphoma
2024-512320-11-00Phase 3Authorised
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of rituximab, methotrexate, procarbazine, busulfan, carmustine and 2 more in Diffuse Large B-Cell Primary Central Nervous System Lymphoma and primary central nervous system lymphoma (PCNSL), sponsored by Universitätsklinikum Freiburg. Primary endpoint: Progression-free survival. Planned start Aug 2023; status: authorised.
02
Drugs
rituximabmethotrexateprocarbazinebusulfancarmustine
03
Conditions
Diffuse Large B-Cell Primary Central Nervous System Lymphomaprimary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on 2024-512320-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512320-11-00.